New hope for lung cancer patients: immunotherapy drug durvalumab tested after chemoradiation

NCT ID NCT06992609

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study tests the drug durvalumab as a consolidation (follow-up) treatment for people with limited-stage small cell lung cancer whose cancer has not grown after chemoradiation. About 70 participants in Spain will receive durvalumab every 4 weeks for up to 24 months. The goal is to see how safe and effective this treatment is in a real-world setting, including patients who may not have been eligible for earlier trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug)
What this could lead to: If successful, this could confirm durvalumab as a standard follow-up treatment to help keep limited-stage small cell lung cancer from returning after initial chemoradiation.
What could go wrong: This is a single-arm, open-label study with only 70 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the drug may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

Research Site

A Coruña, 15006, Spain
Research Site

Badajoz, 06080, Spain
Research Site

Barakaldo, 48903, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08036, Spain
Research Site

Barcelona, 08907, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Málaga, 29010, Spain
Research Site

Oviedo, 33011, Spain
Research Site

Santander, 39008, Spain
Research Site

Seville, 41013, Spain
Research Site

Valencia, 46026, Spain
Research Site

Zaragoza, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.